

b) a suitable pharmaceutical carrier

wherein said drug is a biologically active therapeutic purine compound or a purine nucleoside or purine nucleotide compound and said azide group occurs on the purine base of said purine compound or said purine nucleoside or nucleotide compound.

2-23. (cancelled)

The following claims are new:

24. (New) The composition according to claim 1 wherein said azide group is on the 2 or 6 position of the purine base of said azide derivative.

25. (New) The composition according to claim 1 wherein said drug is a purine compound.

26. (New) The composition according to claim 1 wherein said drug is a purine nucleoside or purine nucleotide compound.

27. (New) The composition according to claim 26 wherein said drug is a purine nucleoside compound.

28. (New) The composition according to claim 26 wherein said drug is a purine nucleotide compound.

29. (New) The composition according to claim 1 wherein said azide derivative has the formula